Pre-Open Movers 06/12: (GLMD) (RH) (PLAY) Higher; (IDRA) (JCAP) (IMMU) Lower (more...)

June 12, 2018 9:26 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Today's Pre-Open Movers

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) 195.6% HIGHER; NASH study shows a statistically significant reduction in liver fat was demonstrated by Magnetic Resonance Spectroscopy (MRS) in patients completing 52 weeks of treatment with Aramchol 400mg vs. placebo. Post hoc analysis of MRS responders, defined by a reduction of ≥5% absolute change from baseline, demonstrated a clinically and statistically significant effect of Aramchol 600mg vs. placebo.

RH (NYSE: RH) 17.6% HIGHER; reported Q1 EPS of $1.33, $0.31 better than the analyst estimate of $1.02. Revenue for the quarter came in at $557.4 million versus the consensus estimate of $563.16 million. RH sees FY2018 EPS of $6.34-$6.83, versus the consensus of $5.91. RH sees FY2018 revenue of $2.53-2.57 million, versus the consensus of $2.55 million. RH sees Q2 2018 EPS of $1.70-$1.77, versus the consensus of $1.51. RH sees Q2 2018 revenue of $655-662 million, versus the consensus of $654.4 million.

Dave & Buster's Entertainment (NASDAQ: PLAY) 14% HIGHER; reported Q1 EPS of $1.04, $0.11 better than the analyst estimate of $0.93. Revenue for the quarter came in at $322.2 million versus the consensus estimate of $322.05 million. The company reaffirmed financial outlook on several key metrics for fiscal 2018.

Lands' End (NASDAQ: LE) 14% HIGHER; reported Q1 EPS of ($0.08), versus ($0.24) reported last year. Revenue for the quarter came in at $299.8 million, versus $268.4 million reported last year.

Idera Pharma (NASDAQ: IDRA) 14% LOWER; Phase 2 Clinical Trial of IMO-8400 in Adult Patients with Dermatomyositis Doesn't Meet Primary Endpoint

Pluristem Therapeutics Inc. (NASDAQ: PSTI) 7.8% HIGHER; announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients mobility. Study results also validate the design of Pluristems ongoing Pivotal Phase III study in CLI, a more severe stage of peripheral arterial disease (PAD) and confirm Pluristems proprietary Bio-Therapeutic approach.

Jernigan Capital, Inc. (NYSE: JCAP) 6.3% LOWER; commenced an underwritten public offering of 3,500,000 shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock.

Pfenex (NYSE: PFNX) 5.3% HIGHER; the company and Alvogen today announced entering into an agreement granting Alvogen exclusive rights to commercialize Pfenexs lead drug candidate, PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Companys Forteo®, in the United States.

Sage Therapeutics (NASDAQ: SAGE) 5.5% HIGHER; announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA). This development plan is intended to support a potential filing for approval of SAGE-217 in the U.S. for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Immunomedics, Inc. (NASDAQ: IMMU) 5% LOWER; commenced an underwritten public offering of $275,000,000 of shares of its common stock. In addition, Immunomedics expects to grant the underwriters a 30-day option to purchase up to an aggregate of an additional $41,250,000 of shares of common stock sold in connection with the offering at the public offering price.

SeaWorld Entertainment (NYSE: SEAS) 4.8% LOWER; Citi downgraded from Neutral to Sell with a price target of $15.00

Weight Watchers (NYSE: WTW) 4.5% HIGHER JPMorgan initiates coverage with an Overweight rating and a price target of $105.00.

AcelRx Pharmaceuticals (NASDAQ: ACRX) 4.2% HIGHER; Cantor Fitzgerald initiates coverage on with an Overweight rating and a price target of $6.00.

KMG Chemicals (NYSE: KMG) 4.2% HIGHER; reported Q3 EPS of $1.10, $0.26 better than the analyst estimate of $0.84. Revenue for the quarter came in at $118.6 million versus the consensus estimate of $112.97 million.

Tesla (NASDAQ: TSLA) 4% HIGHER; KeyBanc raised estimates after checks with sales centers indicate Model 3 deliveries are tracking ~50% higher than prior estimates for the quarter

Urban Outfitters (NASDAQ: URBN) 3.7% HIGHER; disclosed in an SEC filing: Thus far during the second quarter of fiscal 2019, comparable Retail segment net sales are mid teens positive.

Twitter, Inc. (NYSE: TWTR) 3.2% HIGHER; JPMorgan raised its price target to $50.00 (from $39.00) while maintaining an Overweight rating

Sotheby's (NYSE: BID) 2.9% LOWER; Sidoti downgraded from Buy to Neutral.

At Home Group Inc. (NYSE: HOME) 2.9% LOWER; announced today the launch of a proposed underwritten secondary public offering of 8,000,000 shares of its common stock by certain of the Company's existing stockholders, including certain affiliates of AEA Investors LP and Starr Investment Holdings, LLC (collectively, the "Selling Stockholders").

Hercules Capital, Inc. (NYSE: HTGC) 2.7% LOWER; announced that it plans to make a public offering of 6,000,000 shares of its common stock. Hercules also plans to grant the underwriters for the offering an option to purchase up to an additional 900,000 shares of its common stock. Wells Fargo Securities, Morgan Stanley, Jefferies LLC, and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers in this offering, and Compass Point is acting as lead manager in this offering.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Stifel, Keefe, Bruyette & Woods, Cantor Fitzgerald, JPMorgan, Citi, KeyBanc, Morgan Stanley, Jefferies & Co, Twitter, Sidoti & Company, Tesla, Wells Fargo, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, Model 3, FDA